|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The methylation levels of the promoter region of ESR1 and p15 genes in monocytes of leukemia patient were significantly elevated (p < 0.05).
|
29364483 |
2018 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single-cell multicolour FISH was used to demonstrate that the earliest detectable leukaemia subclone contained the STIL-TAL1 fusion and copy number loss of 9p21.3 (CDKN2A/CDKN2B locus), with other copy number alterations including loss of PTEN occurring as secondary subclonal events.
|
29556024 |
2018 |
|
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Long noncoding RNA HOTAIR promotes the self-renewal of leukemia stem cells through epigenetic silencing of p15.
|
30172749 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDKN2B-related piRNAs, hsa_piR_014637 and hsa_piR_011186 were transduced into the leukemia cell line U937 to study the effect of these two piRNAs on cell-cycle progression, apoptosis, heterochromatin formation, CDKN2B methylation and expression.
|
26205624 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
p15(INK4B) and p21(WAF1) are TGF-β targets that are silenced in leukemia by epigenetic mechanisms involving DNA methylation and/or histone modifications.
|
21124069 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, this study (a) establishes that the gene encoding the tumor suppressor p15(INK4b) is a target of CBFbeta-SMMHC, a finding relevant to the leukemogenesis process, and (b) indicates that, in patients with inv(16)-containing AML, reexpression from the INK4b locus in the leukemia would not be predicted to occur using hypomethylating drugs.
|
17283131 |
2007 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Cyclin-dependent kinase inhibitor p15 is frequently inactivated by either methylation or deletion in patients with acute leukemia.
|
15755508 |
2005 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia.
|
15475071 |
2004 |
|
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation of the p15INK4b promoter never seems to occur in solid tumors but is a major gene silencing mechanism in hematological malignancies. p14ARF and p16INK4a promoter methylation often occurs in solid tumors but also in leukemias and lymphomas.
|
15370242 |
2004 |
|
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This profile is distinct from other types of myeloid leukaemias. p15 methylation has a poor prognostic impact on DFS.
|
12899712 |
2003 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, methylation inactivation of the INK4/CDK/RB pathway in leukemia involved primarily p15 and occasionally p16, but not p18 or RB.
|
14513284 |
2003 |
|
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Hypermethylation of the p15(INK4B) gene occurs frequently in leukemia and high-risk MDS.
|
12150726 |
2002 |
|
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, two different patterns of promoter methylation distinguished the leukemias from colorectal cancer: p15 promoter hypermethylation was found only in the leukemias, and p16 promoter hypermethylation occurred only in colon tumors.
|
11584062 |
2001 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results revealed the frequent methylation of p16 and p15 genes in B-ALL and AML despite a low frequency of p16 and p15 deletions and mutations in these leukemias.
|
10634644 |
2000 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Adult T-cell leukemia (ATL) is a retrovirus-associated leukemia with poor prognosis and often has deletions of the p16INK4a and p15INK4b genes on chromosome 9p21.
|
9426690 |
1998 |
|
leukemia
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Recent reports suggest frequent methylation of the p15(INK4b) gene promoter in leukemias, and it has been proposed that this methylation could be necessary for leukemic cells to escape TGF beta regulation.
|
9531610 |
1998 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, the p15INK4B gene was frequently methylated in patients with high-risk MDS (refractory anemia with excess blasts [RAEB], RAEB in transformation [RAEB-t], and overt leukemia evolved from MDS; 14/18 [78%]) compared with patients with low-risk MDS (refractory anemia [RA] and refractory anemia with ring sideroblast [RARS]; 1/12 [8%]).
|
9269757 |
1997 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, ETV6 and p16(INK4A)/p15(INK4B) do not play a significant role in the pathogenesis of infant ALL, further emphasizing the distinctive biology of this subset of leukemias.
|
9204978 |
1997 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, considerable efforts have been made to determine the role of CDK4/6-inhibitors in hematologic malignancies: This article will review alterations of components of the cell-cycle machinery in brief and summarize the role of the CDK4/6-inhibitors p16INK4A, p15INK4B, p18INK4C and p19INK4D in leukemias and lymphomas.
|
9031081 |
1996 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, two putative tumor suppressor gene(s) CDKN2 and MTS2 have been mapped to the 9p21 region, and shown to be deleted in a large number of tumors including leukemias, melanomas, bladder cancers and brain tumors.
|
8689637 |
1996 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
p16INK4A and p15INK4B gene deletions in primary leukemias.
|
7795238 |
1995 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that none of acute myeloblastic leukaemias (four cases) showed the CDK4I alteration, whereas 6/13 (46%) common acute lymphoblastic leukaemias (ALLs) displayed homozygous deletions.
|
8555068 |
1995 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The p15 and p16 genes were either deleted or mutated in myeloid leukaemia lines at a high frequency [6/15 (40%) for p15; 8/15 (53%) for p16] but alterations in primary myeloid leukaemias are much less frequent [2/46 (4%) for p15; 3/46 (6%) for p16].
|
7577621 |
1995 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas.
|
7882348 |
1995 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, it has been shown that the homozygous deletion of the cyclin-dependent kinase-4 inhibitor (CDK4I;p16) gene, which is mapped to chromosome 9p21, is frequently observed in a wide spectrum of human cancers, including leukemias.
|
7919362 |
1994 |